ClinicalTrials.gg
Active, not recruitingNCT05046275Updated Nov 2, 2026

MCR Syndrome in Quebec : Results From NuAge Study

An observational study in Motoric Cognitive Risk Syndrome and Aging Disorder, sponsored by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal. Active, not recruiting at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal · Observational

How we know

Updated Nov 2, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,741
Ages
65 Years and older
Sex
All
01

Study summary

The overall objective of the proposal is to examine the epidemiology of the newly reported "motoric cognitive risk" (MCR) syndrome, which is a pre-dementia syndrome combining subjective cognitive complaint (i.e.; memory complaint) with objective slow gait speed, in the Quebec elderly population.

Cognition and locomotion are two human abilities controlled by the brain. Their decline is highly prevalent with physiological and pathological aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion. Both declines in cognition and locomotion are associated, furthermore the temporal nature of their association has been unclear for a long time. Recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that MCR syndrome is a pre-dementia syndrome, suggesting that low gait performance is the first symptom of dementia. The uniqueness of MCR syndrome is that it does not rely on a complex evaluation or laboratory investigations. Indeed, this syndrome combined subjective cognitive complaint and objective slow gait speed, and is easy to apply in population-based settings.

Prevalence and incidence of MCR syndrome, as well as its association with incidence of cognitive decline and impairment, have never been reported in Canada. Nutrition as a determinant of successful aging: The Quebec longitudinal Study (the NuAge study) is a Quebec population-based observational cohort study performed in healthy older community-dwellers adults which provides a unique opportunity to: 1) obtain reliable estimates of MCR syndrome prevalence and incidence, 2) determine the distribution of clinical and biological (blood biomarkers and genetic) characteristics associated with MCR syndrome, 3) examine the association of MCR syndrome and its biological characteristics with cognitive decline and incidence of cognitive impairment in the Quebec elderly population.

02

Conditions studied

  • Motoric Cognitive Risk Syndrome
  • Aging Disorder
03

In context

Lead sponsor

Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All included participants of NuAge Study were healthy and, in particular, they were cognitively intact at baseline and had no mobility disability.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All included participants of NuAge Study

Exclusion criteria

Exclusion Criteria:

  • no information about cognitive complaint in NuAge database
  • no measure of walking speed in NuAge database
  • no follow-up completed in NuAge database
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,741 participants (actual)
Patient registry
No

Groups and cohorts

  • MCR syndroms

    Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.

    Other: Data analysis

  • Non MCR syndroms

    Summarize of participants' characteristics using means and standard deviations or frequencies and percentages First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.

    Other: Data analysis

Interventions

  • OtherData analysis

    No intervention, data analysis only

06

What researchers measure

Primary outcomes

  1. prevalence of MCR syndrome

    Diagnosis of MCR syndrome following Verghese et al. criteria

    Time frame: 3 years

Secondary outcomes

  1. Cognitive decline and impairment

    Modified Mini-Mental State (3MS) in the NuAge study.

    Time frame: 3 years

  2. Covariates

    Cardio-vascular risk factors and diseases assessed using reported health condition

    Time frame: 3 years

  3. Covariates

    Cardio-vascular risk factors and diseases assessed using physical examination: body mass index

    Time frame: 3 years

  4. Covariates

    Cardio-vascular risk factors and diseases assessed using physical examination: hip waist ratio from hip and waist circumference

    Time frame: 3 years

  5. Covariates

    Cardio-vascular risk factors and diseases assessed using physical examination: blood pressure (value of systolic, diastolic when participants are seated in an upright position in a chair)

    Time frame: 3 years

  6. Biological characteristics

    we selected biomarkers that consistently show associations with clinical risk factors for MCR : IL-6, high-sensitivity CRP and Malondialdehyde (MDA). These biomarkers are associated with individual MCR components. CRP was associated with plaques. Inflammation is hypothesized to be a precursor to neurofibrillary tangles and amyloid plaques; hallmarks of AD. Oxidative stress damage is elevated in vulnerable brain regions in early AD and MCI. We propose a multi-level examination of vascular pathways in MCR including biomarkers (CRP and homocysteine). We include homocysteine, a vascular biomarker, linked to gait and cognitive deficits in other studies.

    Time frame: 3 years

  7. Genetic approach

    we propose to derive polygenic risk scores for cognitive and obesity phenotypes in NuAge, and to examine its predictive validity for MCR syndrome and incident cognitive impairment

    Time frame: 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2020 (actual). Primary completion is estimated for Nov 2027, 83 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Nov 2025 → Nov 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2021
First posted
Sep 16, 2021
StartActual
Nov 3, 2020
Primary completionEst.
Nov 2, 2027was Nov 2025
CompletionEst.
Dec 1, 2027was Dec 2025
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • CRIUGM · Montreal, Canada
Show 1 removed
  • CRIUGM · Montréal, Canada
Nov 2, 2026
Primary completion
Nov 2, 2025→Nov 2, 2027
Nov 2, 2026
Study completion
Dec 1, 2025→Dec 1, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • CRIUGM · Montreal, Canada
    Show 1 removed
    • CRIUGM · Montréal, Canada
    Primary completion Nov 2, 2025→Nov 2, 2027
    Study completion Dec 1, 2025→Dec 1, 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05046275
Lead sponsor
Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Responsible party
Olivier Beauchet (MD, PhD, Senior researcher, Director of laboratory, Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal) — Principal investigator
First posted
Sep 16, 2021
Start date
Nov 3, 2020
Primary completion
Nov 2, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion